2018-04-05
Kancera proposes a preferential rights issue of MSEK 60 to fund the continued clinical development of KAND567
This is a translation of a Press Release in Swedish Stockholm 2018-04-03
Read More
2018-02-20
YEAR END REPORT KANCERA AB (publ) 1st January – 31st December 2017
PERIOD 1 JAN – 31 DEC 2017 IN BRIEF • Net turnover for the period amounted to SEK 0.1 million (0.3 million). For the fourth quarter, turnover amounted to 0.0 MEK (0.1 M). • R & D expenses for the period amounted to...
Read More
2018-02-20
Kancera reports results from clinical Phase I study and strategy for continued development of KAND567
Kancera AB (publ) hereby reports results from a Phase I study in healthy subjects with the immunoregulating drug candidate KAND567. The study shows that KAND567 is safe and well-tolerated up to 500 mg twice daily for 7 days. The...
Read More
2017-12-20
Kancera reports that clinical Phase I study has been completed in the Fractalkine project
Kancera AB (publ) reports that the Phase I study in the Fractalkine project has been completed in accordance with study protocols. In the study, drug characteristics, safety and tolerability have been documented for KAND567 in 62 healthy subjects. The...
Read More
2017-12-11
Kancera acquires additional rights to the Fractalkine project
Kancera AB (publ) has previously announced that the company controls patents and rights to the Fractalkine project, including KAND567, in all diseases except lung diseases. Agreements with AstraZeneca AB and Acturum Real Estate AB now give Kancera AB full...
Read More
2017-11-21
Kancera performs the second partial payment for the Fractalkine project
According to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain number of subjects in the ongoing Phase Ia study.Therefore,...
Read More
2017-11-17
INTERIM REPORT FOR KANCERA AB (publ) 1st January – 30th September 2017
PERIOD 1 JAN – 30 SEPT 2017 IN BRIEF • R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million ) • Operating profit for the period amounted to...
Read More
2017-10-04
KANCERA PROVIDES AN OPERATIONAL UPDATE FOR THE ROR PROJECT
Kancera hereby reports that the company's ROR inhibitor KAN0441571 effectively eliminates ROR1-bearing leukemic cells in a mouse model of human chronic lymphocytic leukemia.
Read More
2017-09-14
Kancera and Recipharm collaborate to manufacture clinical trial supply
Kancera, a development company focused on cancer therapy and Recipharm, a leading contract development and manufacturing organisation (CDMO), have signed a contract for the development and manufacture of the pharmaceutical candidate KAND567.
Read More
2017-09-11
Kancera announces start of Phase 1 Multiple Ascending Dose Trial of KAND567
Kancera today launches the second part of the ongoing clinical Phase I study of KAND567. During this part of the study, KAND567 is administered to groups of healthy subjects in increasing doses, twice a day for seven days. The...
Read More